Generic-Drug Maker Takes Novartis Battle To Full Fed. Circ.
By Andrew Karpan ( February 25, 2022, 5:18 PM EST) -- A Chinese generic-drug maker wants the full Federal Circuit to take a look at a splintered appeals court ruling that allowed Novartis to maintain its monopoly on a multibillion-dollar multiple sclerosis drug for even longer by adding dosage specifications to an older patent covering the drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.